Between August and October 2017, Tisagenlecleucel, marketed as Kymriah (CD-19 specific CAR-T), gained clinical approval to treat B-cell acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), and primary mediastinal B-cell lymphoma (PMBCL) [163]. The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.